Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agaricus blazei Murill Extract in Type II Diabetes Mellitus
NCT00131287Phase 3Completed
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agaricus blazei murill extract in type 2 diabetes mellitus (T2DM). Primary endpoints: Glycated Hemoglobin and Insulin Resistance. Started Jul 2005; status: completed.
02
Drugs
agaricus blazei murill extract
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00131287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131287.